Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence - 02/10/14
M.R., M.S.-F., and J.G.K. were supported by the National Center for Research Resources (grant no. 5UL1RR024143-02), a component of the National Institutes of Health (NIH), and the NIH Roadmap for Medical Research. E.G.-Y. was supported by the Dermatology Foundation Physician Scientist Career Development Award and by a Clinical and Translational Science Award grant from the Rockefeller University. |
|
Disclosure of potential conflict of interest: J. G. Krueger has received consultancy fees from Centocor, Lilly, and Pfizer and has received research support from Amgen, Centocor, Lilly, Merck, and Pfizer. E. Guttman-Yassky reports grants from Janssen, Merck, Bristol Meyers Squib, and Regeneron; grants and personal fees from Leo-Pharma, Dermira, and Celgene; and personal fees from Genentech, Stiefel/GSK, Pfizer, Medimmune, and Anaptysbio outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 134 - N° 4
P. 955-957 - octobre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?